Advanced Search

Study Preview



Study Title and Description

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.



Key Questions Addressed
3 In adult renal transplants, how do immunosuppressive regimens designed to reduce or eliminate exposure to CNI toxicity compare with each other and with full-dose CNI regimens for health outcomes? AND How does the type of induction agent (including when no induction is used) and the use of concurrent immunosuppressive agents affect outcomes of regimens that reduce or eliminate CNI exposure?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.
Author Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., Haas T.
Country Kliniken der med. Hochschule, Zentrum Chirurgie, Hannover, Germany. bjorn.nashan@cdha.nshealth.ca
Year 2004
Numbers Pubmed ID: 15548972
2190 (internal)

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Comparative Effectiveness of Regimens


Results & Comparisons

No Results found.